文献类型： 外文期刊

作者： Qin, Ziliang ¹ ; Nai, Zida ¹ ; Li, Gang ¹ ; He, Xinmiao ² ; Wang, Wentao ² ; Xia, Jiqiao ¹ ; Chao, Wang ² ; Li, Lu ² ; Jiang, Xinpeng ¹ ; Liu, Di ² ;

作者机构： 1.Northeast Agr Univ, Coll Anim Sci & Technol, Harbin 150030, Peoples R China

2.Heilongjiang Acad Agr Sci, Anim Husb Res Inst, Key Lab Combining Farming & Anim Husb, Minist Agr, 368 Xuefu Rd, Harbin 150086, Peoples R China

关键词： microcapsules; PEDV; mucosal immunity; alginate; chitosan

期刊名称：ANIMALS （ 影响因子：3.0； 五年影响因子：3.2 ）

ISSN： 2076-2615

年卷期： 2023 年 13 卷 5 期

页码：

收录情况： SCI

摘要： Simple Summary Porcine epidemic diarrhea virus (PEDV) is an alpha coronavirus that causes major disease outbreaks, producing up to 100% mortality rates in piglets during the first 7 days after birth. In this study, we used microcapsules with inactivated PEDV fed to mice by oral administration to improve the effectiveness of the oral delivery method for protection against PEDV infection, and avoided digestive degradation in the acidic environment of the stomach. In addition, the PEDV microcapsules displayed remarkable storage tolerance to maintain the quality of the PEDV antigen. The PEDV microcapsules delivered the inactivated virus into the gut, stimulating the specific mucosal immune response in mice, which could directly neutralize the enterovirus. The porcine epidemic diarrhea virus, PEDV, which causes diarrhea, vomiting and death in piglets, causes huge economic losses. Therefore, understanding how to induce mucosal immune responses in piglets is essential in the mechanism and application against PEDV infection with mucosal immunity. A method of treatment in our research was used to make an oral vaccine that packaged the inactive PEDV with microencapsulation, which consisted of sodium alginate and chitosan, and adapted the condition of the gut in mice. The in vitro release experiment of microcapsules showed that inactive PEDV was not only easily released in saline and acid solutions but also had an excellent storage tolerance, and was suitable for use as an oral vaccine. Interestingly, both experimental groups with different doses of inactive virus enhanced the secretion of specific antibodies in the serum and intestinal mucus, which caused the effective neutralization against PEDV in the Vero cell by both IgG and IgA, respectively. Moreover, the microencapsulation could stimulate the differentiation of CD11b+ and CD11c+ dendritic cells, which means that the microencapsulation was also identified as an oral adjuvant to help phagocytosis of dendritic cells in mice. Flow cytometry revealed that the B220(+) and CD23(+) of the B cells could significantly increase antibody production with the stimulation from the antigens' PEDV groups, and the microencapsulation could also increase the cell viability of B cells, stimulating the secretion of antibodies such as IgG and IgA in mice. In addition, the microencapsulation promoted the expression of anti-inflammatory cytokines, such as IL-10 and TGF-beta. Moreover, proinflammatory cytokines, such as IL-1, TNF-alpha, and IL-17, were inhibited by alginate and chitosan in the microencapsulation groups compared with the inactivated PEDV group. Taken together, our results demonstrate that the microparticle could play the role of mucosal adjuvant, and release inactivated PEDV in the gut, which can effectively stimulate mucosal and systemic immune responses in mice.